deadli
poxviru
varv
agent
caus
smallpox
fatal
diseas
record
go
back
year
suspect
emerg
bce
sinc
viru
spread
person
person
countri
countri
caus
sever
epidem
human
histori
death
rate
infect
year
elaps
sinc
declar
smallpox
erad
achiev
would
imposs
without
discoveri
vaccin
evolut
poxvirus
vaccin
first
strategi
aim
fight
smallpox
diseas
use
varv
immun
agent
variol
orient
practic
consist
inocul
small
amount
materi
infect
person
healthi
individu
prevent
natur
infect
use
centuri
orient
introduc
europ
physician
emmanuel
timoni
describ
techniqu
practic
later
introduc
ladi
mari
wortley
montagu
unit
kingdom
english
physician
edward
jenner
establish
much
safer
practic
demonstr
anoth
poxviru
infect
use
prevent
smallpox
infect
human
procedur
becam
known
vaccin
deriv
vacca
latin
word
cow
loui
pasteur
propos
vaccin
gener
term
use
prevent
inocul
anim
human
diseas
jennerian
vaccin
practic
viral
strain
expand
new
world
royal
philanthrop
expedit
vaccin
carri
spanish
surgeon
francisco
xavier
balmi
program
expedit
auspic
king
carlo
iv
spain
first
expedit
ship
pita
vaccin
transport
america
armtoarm
propag
orphan
children
la
guayra
venezuela
expedit
divid
two
group
one
salvani
extend
vaccin
south
america
led
balmi
continu
cuba
mexico
acapulco
vaccin
travel
manila
philippin
macau
china
spanish
expedit
firstev
mass
vaccin
campaign
year
establish
expedit
success
jenner
wrote
imagin
annal
histori
furnish
exampl
philanthropi
nobl
extens
time
cpxv
also
hspv
pass
cattl
rabbit
hors
human
use
vaccin
smallpox
globe
howev
certain
evolutionari
point
virus
supersed
vacv
anoth
poxviru
whose
origin
remain
unknown
eventu
becam
studi
poxviru
use
extens
research
tool
latter
half
centuri
saw
emerg
microbiolog
immunolog
scientif
disciplin
mani
pioneer
new
scienc
use
vacv
studi
vaccin
product
introduc
laboratori
taken
scientist
rather
local
physician
entail
improv
qualiti
vaccin
method
distribut
public
health
infrastructur
led
elimin
endem
smallpox
industri
countri
europ
north
america
earli
modif
tradit
product
intern
qualiti
control
vaccin
introduc
shortli
intensifi
smallpox
erad
program
thank
program
last
natur
case
smallpox
occur
somalia
declar
diseas
erad
date
smallpox
human
infecti
diseas
success
erad
earli
recombin
dna
technolog
revolution
molecular
biolog
allow
insert
foreign
dna
poxviru
genom
earli
studi
woodroff
fenner
indic
homolog
recombin
could
occur
genom
two
replic
poxvirus
twentytwo
year
later
marker
rescu
studi
demonstr
fragment
genom
clone
dna
could
recombin
genom
vacv
infect
cell
furthermor
poxviru
express
vector
describ
simultan
laboratori
enzo
paoletti
bernard
moss
recombin
dna
technolog
quickli
becam
wide
use
vaccin
develop
well
research
numer
field
thu
abil
insert
heterolog
gene
poxviru
genom
deepli
improv
vaccin
capabl
poxvirus
longer
use
success
smallpox
vaccin
also
vaccin
wide
rang
heterolog
diseas
name
hepat
b
surfac
antigen
hemagglutinin
influenza
viru
glycoprotein
herp
viru
rabi
viru
glycoprotein
first
foreign
antigen
heterolog
diseas
explor
import
chordopoxvirus
similar
arrang
gene
interchang
promot
conserv
rna
polymeras
transcript
factor
principl
develop
vacv
express
vector
could
applic
poxvirus
genom
sequenc
copenhagen
one
studi
strain
vaccinia
publish
paoletti
cowork
knowledg
abil
insert
delet
select
gene
poxvirus
modifi
la
cart
order
improv
safeti
immunogen
even
abil
select
kill
tumor
cell
articl
review
differ
poxvirus
evolv
natur
control
laboratori
environ
gener
wide
varieti
strain
use
vaccin
candid
homolog
diseas
smallpox
heterolog
diseas
rabi
hivaid
hepat
c
tuberculosi
malaria
leishmaniasi
among
other
complex
diseas
like
cancer
describ
sequenc
differ
poxvirusbas
vaccin
evolv
time
genet
manipul
poxviru
genom
led
develop
vaccin
candid
wide
applic
human
anim
diseas
order
trace
stepbystep
evolut
poxvirus
vaccin
vector
one
start
point
identif
origin
viru
use
jenner
colleagu
earli
stage
vaccin
jenner
vaccin
eightyearold
boy
jame
phipp
cowpox
lesion
milkmaid
sarah
nelm
prove
effect
challeng
smallpox
experi
practic
armtoarm
vaccin
human
expand
around
world
use
cattl
amplifi
viral
stock
howev
vaccin
feasibl
origin
cpxv
displac
eventu
vacv
whose
natur
host
origin
identifi
yet
sever
hypothes
aros
past
origin
vacv
deriv
origin
variola
vaccina
propos
vacv
could
deriv
varv
cpxv
could
hybrid
varv
cpxv
virus
genet
select
use
contamin
vaccin
varv
could
alter
transform
vacv
sever
year
vaccin
human
human
passag
anim
varv
host
rang
gene
studi
anim
indic
hypothesi
dismiss
varv
restrict
human
replic
phenotyp
contrast
wide
host
rang
vacv
hand
cpxv
probabl
exhibit
broadest
host
rang
greatest
genet
divers
among
poxvirus
nonetheless
origin
differ
cpxv
vacv
consid
great
make
origin
probabl
recent
dna
sequenc
data
follow
thread
thought
sever
factor
exacerb
difficulti
identifi
origin
vacv
old
smallpox
vaccin
rare
subject
clonal
purif
method
propag
produc
mixtur
virus
call
quasispeci
fact
deep
genom
sequenc
suggest
modern
vaccin
compris
complex
mixtur
differ
vaccinia
virus
furthermor
practic
cocultiv
smallpox
vaccin
virus
includ
varv
could
produc
recombin
virus
obscur
origin
vacv
strain
context
evid
horizont
gene
transfer
orthopoxvirus
one
exampl
presenc
two
cpxvlike
gene
lister
vacv
strain
anoth
one
repres
small
region
sequenceencod
hspvlike
singl
nucleotid
polymorph
snp
dryvax
subclon
among
orthopoxvirus
cpxv
split
five
differ
monophylet
largest
genom
averag
kbp
around
kbp
larger
vacv
genom
hspv
larger
kbp
five
subtyp
cpxv
encod
gene
present
orthopoxvirus
lead
suggest
modern
orthopoxvirus
evolv
cpxv
reduct
evolut
histor
literatur
state
origin
vaccin
strain
deriv
cpxv
sampl
howev
edward
jenner
also
believ
vaccin
origin
agent
caus
infect
heel
hors
call
greas
suitabl
human
use
passag
cow
also
argu
could
possibl
jenner
confus
greas
dermat
verrucosa
horsepox
variola
equina
fact
equin
use
side
side
vaccin
earli
stage
smallpox
epidem
sever
exampl
earli
vaccin
hspv
exampl
dr
de
carro
vienna
dr
sacco
milan
commun
practic
jenner
dr
loy
also
show
hors
suscept
poxviru
confer
immun
cpxv
hspv
caus
human
immun
system
react
expos
smallpox
viru
creat
longterm
immun
orthopoxvirus
antigen
relat
immun
nearli
orthopoxviru
protect
challeng
anoth
orthopoxviru
phylogenet
analysi
conserv
region
poxviru
genom
indic
hspv
close
relat
sequenc
isol
vacv
rabbitpox
viru
furthermor
interest
experiment
infect
hors
vacv
produc
clinic
sign
hspv
recent
articl
studi
poxviru
evolut
author
claim
probabl
rout
vacv
strain
might
evolv
stock
viru
contain
ancestr
hspvlike
viru
conclus
aros
identifi
gene
seem
subject
widespread
neg
select
vacv
strain
nonetheless
order
better
understand
relationship
hspv
vacv
import
obtain
genom
sequencesofhspv
endeavor
extrem
challeng
hspv
seem
extinct
vaccin
procedur
perform
year
differ
countri
around
world
without
intern
standard
fact
reliabl
assay
method
qualiti
control
develop
implement
consequ
vacv
strain
use
differ
countri
differ
biolog
properti
first
vacv
strain
receiv
name
regard
health
agenc
countri
region
origin
widelyus
summar
tabl
addit
larg
number
distribut
around
involv
global
effort
erad
smallpox
unit
state
vaccin
smallpox
deriv
stock
suppli
new
york
citi
health
depart
nycbh
use
strain
dr
river
develop
two
attenu
strain
viru
cvii
pass
nycbh
rabbit
test
chick
embryo
caus
less
reactogen
comparison
parent
strain
abil
mediat
protect
smallpox
question
strain
also
distribut
laboratori
receiv
differ
name
ihd
noguchi
wr
passag
differ
organ
brain
test
rabbit
mice
thu
modifi
biolog
properti
sever
studi
show
strain
wr
ihd
present
increas
level
pathogen
advers
effect
human
limit
use
vaccin
choic
earli
step
fight
smallpox
anoth
vaccin
deriv
nycbh
passag
cow
wyeth
laboratori
marietta
pa
usa
vaccin
call
nonclon
vaccin
prepar
calf
lymph
distribut
freezedri
vaccin
natur
nonclon
origin
recent
character
genet
analysi
show
complex
differ
vacv
substrain
classifi
four
subgroup
accord
genom
structur
analysi
vaccin
still
one
current
usalicens
smallpox
vaccin
second
vaccin
deriv
nycbh
licens
usa
aventi
pasteur
smallpox
vaccin
apsv
apsv
manufactur
maintain
frozen
prepar
clinic
studi
vaccin
stop
myocard
case
aros
vaccin
trial
nycbh
also
believ
parent
strain
vaccin
strain
deriv
ecuador
use
former
ussr
also
wide
use
erad
smallpox
india
lister
strain
prepar
skin
sheep
wide
use
vaccin
smallpox
produc
pock
chorioallanto
membran
easier
count
comparison
vacv
strain
intern
refer
center
later
produc
seed
lot
strain
distribut
vaccin
produc
develop
countri
commerci
lancyvaxina
berna
biotech
deriv
strain
formul
vaccin
lyophil
product
prepar
calf
lymph
tian
tan
viru
extens
vacv
strain
use
vaccin
smallpox
china
sinc
name
tian
tan
acquir
viru
isol
beij
templ
heaven
central
nation
epidem
bureau
initi
hous
viru
use
china
russian
strain
vaccinia
use
legend
tell
vaccin
isol
mr
qi
changq
patient
smallpox
passag
skin
monkey
rabbit
cow
howev
stori
lack
scientif
credibl
varv
infect
restrict
human
contain
host
rang
gene
need
infect
monkey
rabbit
cow
moreov
recent
genom
sequenc
demonstr
tian
tan
clearli
vacv
share
common
origin
copenhagen
strain
differ
monkeypox
mpxv
varv
hspv
intensifi
erad
campaign
smallpox
start
particular
strain
offici
recommend
respons
inquiri
smallpox
erad
unit
advis
either
lister
nycbh
strain
use
addit
potenc
safeti
differ
vaccin
standard
lyophil
recommend
vaccin
batch
might
contain
least
pockform
unit
per
ml
vacv
strain
use
earli
vaccin
campaign
smallpox
ankara
use
turkey
aosta
itali
bohemia
czechoslovakia
bordeaux
africa
portug
massachusett
argentina
gam
ussr
mrivp
ussr
per
ussr
williamsport
usa
lmc
uk
hamburg
germani
sweden
sweden
finland
finland
patwadang
india
vienna
bulgaria
spain
spain
tom
ussr
chambon
franc
africa
last
natur
infect
smallpox
occur
somalia
erad
possibl
due
vaccin
also
date
anim
reservoir
smallpox
human
exist
sinc
erad
varv
offici
retain
two
collabor
center
center
diseas
control
prevent
cdc
atlanta
georgia
usa
state
research
center
virolog
biotechnolog
vector
novosibirsk
russian
feder
although
smallpox
erad
public
health
threat
could
potenti
reemerg
bioterrorist
threat
risk
scenario
includ
anim
poxvirus
genet
engin
manipul
poxvirus
thu
prevent
potenti
risk
due
side
effect
firstgener
vacv
vaccin
safer
vacv
strain
improv
develop
posterad
era
order
standard
procedur
control
possibl
microbi
contamin
avoid
sensibil
allergen
anim
protein
accompani
vaccin
use
live
anim
growth
differ
vaccin
substitut
tissu
cultur
system
embryon
chicken
egg
secondgener
vaccin
list
tabl
lister
first
vacv
strain
use
product
cellcultur
deriv
smallpox
vaccin
passag
rabbit
kidney
cell
chorioallanto
membran
chicken
embryo
ce
primari
cell
deriv
chicken
embryo
thu
first
secondgener
listerbas
vaccin
rivm
produc
use
rabbit
kidney
cell
viru
passag
directli
calf
lymph
vaccin
cell
passag
perform
gener
vaccin
freezedri
vaccin
demonstr
similar
take
rate
neutral
antibodi
calf
lymphderiv
vaccin
vaccin
use
clinic
trial
netherland
indonesia
without
produc
sever
complic
lister
strain
grown
chorioallanto
membran
ce
use
militari
forc
israel
sever
complic
observ
furthermor
sanofi
pasteur
develop
anoth
secondgener
vacv
vaccin
passag
batch
firstgener
lister
vaccin
three
passag
ce
primari
cell
cep
vaccin
listercep
similar
immunogen
safeti
comparison
parent
firstgener
lister
vaccin
addit
bavarian
nordic
bn
also
manufactur
vaccin
use
lister
strain
call
elstreebn
passag
ce
cell
demonstr
safeti
immunogen
preclin
studi
monkey
human
clinic
trial
conduct
vaccin
also
prepar
chicken
embryo
fibroblast
cef
cell
japan
smallpox
erad
show
adequ
safeti
profil
effect
well
document
sever
secondgener
vacv
vaccin
also
prepar
use
nycbh
seed
strain
first
candid
grown
cell
cultur
use
clinic
trial
us
armi
stop
due
absenc
adequ
take
rate
observ
nonetheless
stock
anoth
cellcultur
stock
develop
cell
receiv
name
cellcultur
smallpox
vaccin
ccsv
headtohead
phase
clinic
trial
comparison
perform
dilut
ccsv
vaccin
show
take
rate
statist
signific
differ
immunogen
comparison
use
vaccin
militari
personnel
anoth
vaccin
candid
deriv
nycbh
acambi
vaccin
deriv
clone
isol
origin
six
clone
isol
safeti
evalu
suckl
mice
rabbit
signific
differ
neurovirul
observ
among
differ
clone
clone
reduc
neurovirul
still
maintain
lesion
size
compar
vaccin
clone
select
grown
first
cell
later
vero
cell
gener
vaccin
preclin
studi
demonstr
strain
less
neurovirul
comparison
demonstr
similar
immunogen
phase
clinic
trial
nonetheless
phase
ii
iii
clinic
trial
caus
myocard
associ
vaccin
food
drug
administr
fda
approv
vaccin
smallpox
human
use
sanofi
pasteur
manufactur
vaccin
nycbh
also
use
parent
seed
strain
develop
anoth
secondgener
vacv
vaccin
term
obtain
passag
cell
south
korea
compar
firstgener
lancyvaxina
vaccin
show
similar
reactogen
immunogen
neurovirul
preclin
trial
moreov
phase
clinic
trial
show
overal
rate
cutan
take
reaction
humor
cellular
immunogen
vaccine
seriou
advers
reaction
observ
howev
one
case
possibl
gener
vaccinia
infect
occur
one
studi
group
strain
also
deriv
nycbh
western
reserv
wr
neurovirul
strain
wide
histori
passag
first
rabbit
follow
mice
cell
cultur
duke
isol
vaccin
patient
receiv
vaccin
new
research
prove
vacv
ihdj
intern
health
depart
also
share
common
ancestor
ie
nycbh
studi
secondgener
vaccin
demonstr
although
cellcultur
vaccin
improv
control
standard
lack
previou
vaccin
use
replicationcompet
strain
vacv
repres
associ
risk
seriou
advers
event
still
control
sever
first
secondgener
poxviru
strain
express
differ
heterolog
antigen
use
vaccin
candid
wide
rang
diseas
tabl
summar
relev
recombin
poxvirus
use
purpos
member
poxviru
famili
also
extens
use
vaccin
vector
homolog
heterolog
diseas
see
tabl
tabl
sever
exampl
vaccin
base
avipoxviru
suipoxviru
capripoxviru
leporipoxviru
parapoxviru
belong
chordopoxvirina
subfamili
avipoxvirus
apv
belong
chordopoxvirina
subfamili
poxvirida
famili
infect
caus
diseas
poultri
pet
wild
bird
transmit
via
bite
insect
aerosol
usual
name
basi
bird
speci
viru
first
isol
character
apv
infect
report
affect
speci
order
bird
howev
knowledg
molecular
biolog
properti
apv
larg
restrict
canarypox
viru
cnpv
fowlpox
viru
fwpv
full
genom
sequenc
avail
despit
shorter
fwpv
genom
molecular
comparison
show
cnpv
fwpv
share
amino
acid
ident
signific
genesequ
rearrang
delet
insert
cnpv
exhibit
broader
tissu
tropism
permiss
avian
host
fwpv
gener
associ
higher
mortal
rate
virus
describ
unabl
replic
dissemin
infect
nonhuman
primat
human
studi
shown
replic
fwpv
nonpermiss
mammalian
cell
cultur
presenc
infecti
viral
particl
occasionalpres
immatur
form
matur
intracellular
viru
infect
cell
howev
recent
studi
demonstr
despit
detect
matur
virion
fwpvinfect
vero
cell
new
progeni
infecti
due
natur
hostrang
restrict
avian
speci
effici
express
heterolog
gene
also
human
cell
abil
induc
antigenspecif
humor
cellular
immun
respons
cnpv
fwpv
repres
altern
safer
vector
context
sever
recombin
apv
evalu
vaccin
candid
wide
rang
infecti
diseas
apvbas
vaccin
licens
commerci
veterinari
use
anim
infect
like
vaccin
also
use
human
diseas
futur
tabl
summar
relev
recombin
avipoxvirus
use
vaccin
vector
differ
diseas
furthermor
poxviru
vector
chordopoxvirina
subfamili
orthopoxviru
raccoon
poxviru
parapoxviru
capripoxviru
suipoxviru
myxomaviru
wide
use
vaccin
candid
sever
anim
human
diseas
see
tabl
show
good
level
safeti
immunogen
obtain
late
japan
passag
parent
lister
strain
time
primari
rabbit
kidney
prk
epitheli
cell
low
temperatur
follow
isol
one
clone
grow
lowest
titer
monkey
kidney
vero
cell
passag
six
addit
time
prk
cell
obtain
clone
latter
stock
clone
passag
three
time
prk
cell
gener
clone
final
stock
replic
poorli
vero
cell
form
small
plaqu
chick
chorioallanto
membran
cam
prk
cell
thu
grow
produc
infecti
particl
spread
poorli
cell
cultur
compar
origin
lister
strain
temperaturerestrict
display
limit
host
rang
lower
pathogen
advers
effect
anim
model
contain
frameshift
singl
nucleotid
delet
gene
encod
extracellular
envelop
viru
eev
protein
essenti
eev
format
analysi
fullgenom
sequenc
show
larg
delet
compar
parent
lister
strain
shown
induc
protect
immun
orthopoxviru
challeng
mice
rabbit
nonhuman
primat
moreov
safe
immunogen
attenu
smallpox
vaccin
immunodefici
mice
vacciniana
human
howev
two
import
main
concern
vaccin
first
sinc
key
attenu
mutat
one
base
delet
result
frameshift
earli
truncat
protein
viru
revert
back
wild
type
growth
avoid
phenomenon
new
version
complet
delet
gene
gener
second
concern
relat
fact
vacv
protein
primari
target
antigen
gener
neutral
antibodi
eev
thu
due
presenc
mutat
fail
induc
either
eevneutr
antibodi
antibodi
human
featur
may
make
less
effici
vaccin
protect
poxvirus
remain
seen
whether
strain
induc
similar
level
neutral
antibodi
varv
vaccin
strain
nevertheless
combin
delet
gene
caus
lack
antivacv
vector
immun
insert
heterolog
antigen
vacv
tk
ha
loci
good
strategi
use
vaccin
vector
infecti
diseas
thu
report
attenu
recombin
express
clade
b
env
sarscov
spike
protein
abl
induc
robust
humor
cell
immun
respons
sarsspecif
neutral
antibodi
vaccin
mice
rabbit
respect
thu
one
safest
live
attenu
replicationcompet
vaccin
sole
smallpox
vaccin
licens
japan
recent
recommend
one
prefer
smallpox
vaccin
stockpil
furthermor
promis
vaccin
vector
infecti
diseas
vacv
di
strain
gener
success
passag
parent
dairen
strain
onedayold
egg
di
form
small
plaqu
cam
grow
well
chick
embryo
fibroblast
cef
cell
unabl
grow
mammalian
cell
di
highli
restrict
host
rang
mutant
contain
great
delet
kb
left
termin
region
vacv
genom
result
loss
put
orf
gene
includ
hostrang
gene
insert
gag
gene
delet
region
di
induc
high
level
cytotox
lymphocyt
immun
mice
furthermor
recombin
vacv
di
express
simian
immunodefici
viru
siv
gag
pol
antigen
induc
sivspecif
cellular
humor
immuneresponsesin
mice
immun
nonhuman
primat
result
suggest
recombin
vacv
di
safe
effici
transient
replicationdefici
viral
vector
use
vaccin
regimen
vaccin
develop
strain
vacv
gener
passag
respect
friend
erythroleukemia
fel
cell
line
persist
infect
wr
strain
persist
infect
fel
cell
mutant
suffer
larg
delet
mda
left
terminu
viral
genom
alter
structur
protein
role
morphogenet
pathway
exhibit
small
plaqu
size
phenotyp
compar
wr
parent
viru
highli
attenu
maintain
replic
capac
mammalian
cell
line
genom
recent
sequenc
show
multipl
point
mutat
specif
gene
delet
recombin
base
mutant
earli
passag
fel
cell
express
parasit
antigen
malaria
leishmaniasi
shown
elicit
protect
challeng
parasit
primeboost
regimen
mice
mva
highli
attenu
vacv
strain
gener
germani
passag
turkish
smallpox
vaccin
chorioallanto
vacv
ankara
cva
strain
time
primari
cef
cell
extens
serial
passag
cell
cultur
mva
lost
nearli
around
kb
parent
cva
genom
contain
sever
point
mutat
larg
delet
compar
cva
mainli
left
right
termin
region
mani
gene
delet
involv
host
rang
modul
host
immun
respons
result
dramat
evolutionari
genom
modif
mva
lost
abil
produc
infecti
progeni
viru
almost
mammalian
cell
line
includ
human
cell
replic
effici
cef
cell
thu
cell
mva
produc
earli
intermedi
late
protein
immatur
virion
form
inabl
replic
human
cell
mva
would
like
safe
administ
peopl
condit
would
allow
routin
smallpox
vaccin
fact
mva
use
safe
highli
attenu
smallpox
vaccin
last
decad
smallpox
erad
campaign
inocul
peopl
germani
advers
side
effect
although
efficaci
smallpox
remain
untest
sinc
mva
wide
studi
thirdgener
smallpox
vaccin
abl
induc
antibodi
respons
similar
well
protect
mous
nonhuman
primat
challeng
model
howev
high
dose
multipl
dose
mva
administr
elicit
immun
protect
compar
smallpox
vaccin
nevertheless
protect
elicit
mva
rapid
one
induc
fulli
replicationcompet
vaccin
mainli
due
induct
rapid
immun
activ
innat
immun
respons
furthermor
mva
lack
sever
vacv
immunomodulatori
gene
involv
evas
host
immun
respons
solubl
receptor
type
ii
ifn
cytokin
chemokin
whose
absenc
allow
enhanc
antigen
present
immunogen
fact
delet
innat
immun
evas
gene
lead
increas
proinflammatori
cytokin
migrat
immun
cell
great
influenc
abil
elicit
adapt
immun
thu
mva
evalu
smallpox
vaccin
differ
anim
model
sever
human
clinic
trial
found
safe
immunogen
without
develop
clinic
diseas
although
mva
vaccin
test
directli
human
efficaci
varv
test
monkeypox
trigger
protect
term
mva
registr
smallpox
vaccin
european
medicin
agenc
regist
vaccin
imvanex
health
canada
also
regist
vaccin
person
year
older
usa
evalu
fda
among
poxvirus
mva
tip
iceberg
one
promis
poxviru
vector
review
enorm
effort
put
use
mva
vaccin
vector
sever
preclin
human
clinic
trial
develop
use
mva
vaccin
candid
extens
number
infecti
diseas
hivaid
malaria
tuberculosi
hepat
c
cancer
among
mani
other
tabl
summar
use
mva
preclin
human
clinic
trial
vaccin
candid
differ
viral
bacteri
parasit
infecti
diseas
gener
trovac
attenu
fowlpox
vaccin
strain
deriv
duvett
strain
subject
four
success
plaqu
purif
one
plaqu
isol
amplifi
primari
cef
cell
viral
stock
design
trovac
gener
deposit
american
type
cultur
collect
atcc
access
number
highli
attenu
form
fwpv
deriv
wildtyp
fowlpox
viru
serial
passag
cef
cell
genom
fulli
sequenc
found
harbor
sever
deletionsinsert
gene
modif
compar
sequenc
wildtyp
fwpv
strain
alvac
plaquepurifi
clone
deriv
attenu
cnpv
obtain
wildtyp
strain
serial
passag
cef
cell
extens
evalu
preclin
studi
nonhuman
primat
wide
use
human
clinic
trial
hivaid
vaccin
candid
licens
veterinari
use
alvacbas
vector
report
well
toler
safe
human
first
sign
efficaci
hivaid
vaccin
candid
although
modest
obtain
phase
iii
clinic
trial
use
alvacbas
vector
poxvirus
encod
mani
protein
involv
host
innat
immun
evas
secret
protein
bind
neutral
ifn
cytokin
chemokin
intracellular
protein
inhibit
apoptosi
signal
pathway
lead
product
ifn
proinflammatori
cytokin
chemokin
thu
delet
vacv
gene
involv
immunemodul
hostrang
accessori
nucleotid
metabol
gene
one
techniqu
wide
use
gener
novel
poxviru
vector
attenu
profil
novel
vaccin
candid
optim
immunogen
one
best
exampl
attenu
vacv
vector
gener
delet
viral
gene
nyvac
vacv
strain
deriv
plaqueclon
isol
copenhagen
strain
vacvcop
precis
delet
open
read
frame
orf
delet
gene
includ
orf
gene
tk
ha
involv
pathogen
virul
hostrang
function
result
vector
exhibit
dramat
reduc
abil
replic
varieti
human
mammalian
cell
type
highli
attenu
sinc
fail
dissemin
immunodefici
mice
unabl
produc
infecti
viru
human
despit
limit
replic
human
mammalian
cell
nyvac
provid
high
level
gene
express
trigger
antigenspecif
immun
respons
deliv
foreign
protein
anim
human
reason
nyvacbas
recombin
underintensepreclin
clinic
investig
recombin
vaccin
multipl
infecti
diseas
see
tabl
studi
involv
delet
immunemodul
vacv
gene
perform
vacv
wr
strain
gener
result
show
delet
mani
vacv
gene
attenu
viru
impact
immunogen
variabl
thu
delet
immunomodulatori
vacv
gene
differ
strain
mainli
wr
mva
increas
immunogen
vacv
antigen
describ
vacv
gene
howev
delet
immunomodulatori
gene
effect
virul
pathogen
enhanc
immunogen
vacv
moreov
delet
mva
significantli
affect
vacvspecif
cell
immunogen
balbc
mice
furthermor
wyeth
strain
delet
code
region
immunomodulatori
gene
product
increas
immunogen
vector
compar
parent
vacv
recent
sever
delet
tian
tan
strain
perform
analyz
exampl
recombin
tian
tan
vacv
express
gag
pol
env
gene
delet
gene
highli
attenu
retain
high
immunogen
parent
viru
elicit
strong
humor
cellular
respons
target
gene
addit
report
delet
lister
strain
five
major
nonessenti
region
delet
mva
enhanc
attenu
although
vacvspecif
immun
respons
similar
tradit
smallpox
vaccin
nonetheless
introduct
six
major
genom
delet
mva
parent
vacv
cva
suffici
reproduc
mvalik
phenotyp
cell
cultur
mice
combin
insert
heterolog
antigen
poxviru
vector
delet
immunomodulatori
vacv
gene
promis
novel
approach
optim
poxviru
vaccin
vector
enhanc
immunogen
foreign
antigen
strategi
wide
use
gener
optim
recombin
mva
nyvac
vector
express
antigen
use
hivaid
vaccin
candid
contain
singl
multipl
delet
immunomodulatori
vacv
gene
antagon
hostspecif
immun
respons
new
optim
recombin
mva
nyvac
vaccin
vector
lack
vacv
immunomodulatori
gene
test
mice
nonhuman
primat
overal
result
show
induc
enhanc
cellular
humor
immun
respons
thu
remov
vacv
immunomodulatori
gene
block
host
immun
respons
infect
use
method
enhanc
antigenspecif
immun
respons
induc
differ
poxvirusbas
vaccin
candid
dissect
immun
profil
induc
novel
poxviru
vector
delet
singl
gene
gene
famili
necessari
find
optim
poxviru
vector
could
enter
futur
human
clinic
trial
test
whether
provid
protect
infect
fact
system
biolog
profil
nyvac
vector
express
antigen
lack
ifn
inhibitor
reveal
human
macrophag
distinct
gene
signatur
correl
immun
paramet
relev
protect
gene
signatur
also
defin
hiv
vaccin
candid
mvab
mvac
summari
poxviru
gene
delet
context
poxvirusbas
vaccin
vector
differ
infecti
diseas
shown
tabl
one
advantag
replicationdefici
virus
safeti
profil
howev
postul
efficaci
virus
restrict
due
failur
replic
limit
antigen
accumul
viru
infect
reason
restor
replic
compet
human
cell
togeth
delet
specif
immunomodulatori
vacv
gene
strategi
improv
efficaci
poxvirusbas
vector
case
nyvac
vector
restor
replic
capac
obtain
reinsert
andor
host
rang
gene
viral
genom
report
new
construct
still
attenu
acquir
new
biolog
properti
distinct
parent
nyvac
make
potenti
improv
vaccin
vector
candid
human
applic
see
tabl
furthermor
gene
signatur
replicationcompet
nyvac
vector
express
gene
term
nyvacckc
human
dendrit
cell
describ
anoth
categori
gene
use
improv
poxvirus
vaccin
vector
encod
costimulatori
molecul
gmcsf
strategi
significantli
enhanc
immunogen
efficaci
poxviru
vector
vaccin
differ
infecti
diseas
extens
use
cancer
see
section
howev
limit
insert
immunomodul
ramshaw
colleagu
discov
insert
mous
recombin
ectromelia
viru
suppress
antivir
cellmedi
immun
respons
explor
insert
cytokin
sever
poxvirus
significantli
increas
effici
recombin
viru
pathogen
directli
inhibit
develop
immun
crucial
viral
clearanc
optim
gene
express
poxvirusbas
vaccin
address
improv
gener
immun
respons
heterolog
antigen
thu
regul
antigen
express
level
altern
vaccinedesign
strategi
adopt
induc
antigenspecif
immun
respons
regard
lateearli
vacv
promot
first
strategi
use
induc
heterolog
antigen
express
remov
poxviru
transcript
termin
signal
insert
gene
regul
gene
express
bacteriophag
promot
vaccinia
modifi
vaccinia
short
synthet
earlyl
ps
promot
use
altern
increas
quantiti
heterolog
antigen
express
infect
recent
demonstr
effici
antigen
process
present
surfac
infect
cell
influenc
recognit
fact
vacv
antigen
recogn
cell
rank
among
top
term
mrna
express
correl
time
viral
antigen
express
gener
antigenspecif
immun
respons
reason
effort
toward
develop
new
poxviru
vaccin
candid
focus
use
promot
improv
time
rather
quantiti
antigen
express
deep
analysi
vacv
transcriptom
two
group
defin
two
categori
earli
gene
base
tempor
express
base
studi
endogen
poxvir
earli
promot
compar
ps
promot
promot
induc
high
level
earli
antigen
express
cellular
immunogen
similar
ps
promot
recent
studi
demonstr
possibl
design
poxviru
promot
improv
earli
antigen
express
antigenspecif
cell
respons
regard
synthet
earli
promot
phyb
nativ
earli
promot
like
present
repeat
motif
contain
earli
promot
element
altern
strategi
poxviru
promot
design
optim
earli
promot
element
bioinformat
analysi
indic
lateearli
optim
leo
promot
new
promot
abl
increas
express
heterolog
antigen
specif
immun
respons
compar
ps
repres
excel
prototyp
gener
safe
poxviru
recombinantbas
vaccin
potenti
antigen
express
immun
respons
poxvirus
repres
strong
contend
cancer
vaccin
develop
given
abil
express
larg
foreign
gene
capac
induc
strong
cytotox
lymphocyt
ctl
respons
broad
tissu
tropism
fast
replic
lysi
infect
cell
potenti
take
advantag
tumor
microenviron
deregul
cell
cycl
control
partial
block
ifn
respons
apoptosi
immun
evas
absenc
dna
integr
host
genom
safeti
featur
could
potenti
solut
rang
issu
character
cancer
low
immun
respons
gener
tumorassoci
antigen
taa
strong
immunesuppressor
tumor
environ
antivir
immun
respons
elicit
vector
concern
regard
safeti
vaccin
use
site
viru
infect
andor
replic
toxic
transgen
express
vaccineassoci
side
effect
first
time
poxviru
assay
potenti
vector
treat
tumor
case
purifi
vaccin
lymph
use
treat
variou
skin
cancer
local
inject
within
sever
poxvirusbas
strategi
deploy
analyz
preclin
stage
cancer
vaccin
develop
vacv
fwpv
cnpv
combin
vector
repres
major
seen
tabl
describ
infecti
diseas
develop
differ
vaccin
cancer
variou
approach
involv
insert
heterolog
gene
common
poxviru
strain
immunotherapi
express
taa
eg
oncofet
antigen
psa
cea
express
immunomodulatori
gene
eg
costimulatori
gmcsf
express
suicid
gene
eg
cytosin
deaminas
purin
nucleosid
phosphorylas
express
gene
use
imag
support
combin
therapi
thyroid
sodium
iodid
symport
ni
hand
differ
artifici
evolut
poxvirus
perform
direct
natur
oncolyt
capac
famili
gener
tumortailor
virus
grow
higher
extent
tumor
cell
microenviron
way
poxvirus
engin
delet
specif
gene
involv
nucleotid
metabol
interferon
respons
cell
cycl
cell
function
abnorm
regul
tumor
cell
eg
likewis
combin
differ
strategi
mention
evalu
altogeth
differ
immun
protocol
strategi
especi
promis
reflect
signific
number
human
clinic
trial
phase
ii
iii
carri
target
differ
type
cancer
melanoma
breast
prostat
liver
cancer
sinc
jenner
first
describ
applic
viru
isol
cow
demonstr
efficaci
vaccin
smallpox
poxviru
famili
constant
chang
humanmad
adapt
soon
realiz
famili
virus
quit
larg
infect
wide
rang
anim
speci
orthopoxviru
genu
replic
product
human
variola
strain
caus
smallpox
due
health
problem
inher
smallpox
one
dread
diseas
human
mankind
death
rate
major
effort
dedic
erad
scourg
declar
world
free
smallpox
along
way
mani
studi
aim
understand
biolog
group
anim
virus
major
scientif
discoveri
emerg
profound
effect
biolog
whole
fact
scientif
concept
relev
basi
immunolog
antibodi
respons
viru
infect
compon
viru
particl
dna
protein
lipid
presenc
dnadepend
rna
polymeras
virion
machineri
mrna
synthesi
modif
format
two
form
infecti
viru
particl
exist
multipl
viral
gene
capac
counteract
host
immun
respons
abil
viru
accept
insert
heterolog
foreign
gene
viral
genom
remov
multipl
viral
gene
among
featur
defin
plastic
famili
virus
turn
increas
knowledg
live
virus
cell
urgenc
develop
attenu
vaccin
promot
use
differ
anim
model
cell
cultur
system
viru
isol
result
number
vaccin
strain
emerg
differ
countri
whole
genom
sequenc
develop
realiz
occurr
differ
genet
chang
within
viru
genom
larg
dna
high
fidel
polymeras
surpris
order
observ
genet
alter
delet
point
mutat
multipl
passag
viru
cell
cultur
need
attenu
effort
result
isol
identif
wide
use
poxviru
vaccin
strain
candid
mainli
deriv
nycbh
dryvax
lister
tian
tan
mva
nyvac
alvac
first
entir
dna
sequenc
copenhagen
strain
vacv
describ
number
poxviru
whole
genom
sequenc
increas
consider
inform
provid
facilit
identif
mutat
correl
attenu
phenotyp
inde
found
case
strain
deriv
lister
caus
attenu
frameshift
singl
nucleotid
delet
gene
thu
old
approach
allow
appear
spontan
mutat
viru
genom
cell
passag
longer
method
choic
fact
soon
knowledg
develop
biolog
role
viral
gene
newli
design
vector
develop
like
nyvac
vector
deriv
copenhagen
strain
select
delet
open
read
frame
orf
dna
sequenc
method
togeth
easi
method
remov
incorpor
select
gene
viral
genom
consider
expand
understand
role
viralencod
immun
modul
use
poxviru
vector
vaccin
candid
multipl
vaccin
candid
develop
base
member
poxviru
famili
abil
express
gene
interest
host
differ
origin
wide
use
poxviru
vector
deriv
mva
nyvac
alvac
none
vector
approv
human
usag
viru
recombin
vaccin
promis
result
obtain
larg
number
preclin
clinic
trial
presag
nottoodist
applic
recombin
viral
vector
vaccin
human
multipl
diseas
exemplifi
partial
efficaci
alvac
hiv
phase
iii
clinic
trial
thailand
recent
outbreak
ebola
efficaci
result
observ
nonhuman
primat
primeboost
combin
adenoviru
mva
vector
express
ebola
gp
protein
protocol
might
implement
part
phase
iii
clinic
trial
initi
variou
site
africa
also
abund
preclin
inform
proven
efficaci
vector
model
diseas
expect
next
step
poxviru
vaccin
evolut
fact
whole
viru
genom
sequenc
reconstitut
synthesi
nucleotid
viru
genom
easili
manipul
genet
new
inform
role
viral
gene
interact
host
cell
known
indic
vaccin
purpos
novel
vector
high
specif
trigger
b
cell
immun
respons
high
protect
capac
develop
inde
novel
vector
trigger
high
immun
respons
foreign
express
antigen
gener
either
select
delet
viral
immun
modul
incorpor
host
rang
gene
incorpor
cytokineschemokin
gene
inducersactiv
immun
respons
still
unclear
need
develop
vector
trigger
potent
immun
respons
ie
high
elispot
number
select
trigger
longterm
memori
b
cell
respons
index
potenc
case
efficaci
need
model
system
well
definit
immun
correl
protect
implement
system
biolog
approach
preclin
clinic
trial
nonhuman
primat
vaccin
individu
identifi
gene
signatur
relev
protect
could
aid
select
optim
immunogen
still
much
remain
learn
biolog
role
play
mani
virusencod
immun
modul
vaccin
purpos
import
advanc
vector
well
character
term
pathogen
immunogen
molecular
signatur
bestinclass
candid
defin
direct
headtohead
comparison
immun
characterist
among
vector
sinc
final
aim
develop
vaccin
fulli
protect
diseas
known
progress
advanc
gener
optim
poxviru
vector
studi
behavior
anim
model
clinic
trial
nonetheless
predict
case
singl
poxviru
recombin
vector
might
suffici
fight
diseas
like
case
heterolog
vector
combin
like
dna
rna
protein
attenu
viral
vector
use
togeth
primeboost
protocol
fight
complex
diseas
overal
seen
remark
chang
poxviru
evolut
time
viru
isol
anim
cell
cultur
select
target
viral
gene
scientif
inform
gain
vector
biolog
preclin
clinic
trial
advanc
show
health
benefit
vector
behavior
anticip
bright
futur
poxvirusbas
vaccin
field
